agalsidase alfa
HGT-REP-081
Phase 3 mab completed
Quick answer
agalsidase alfa for Fabry Disease is a Phase 3 program (mab) at Takeda with 3 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda
- Indication
- Fabry Disease
- Phase
- Phase 3
- Modality
- mab
- Status
- completed